Alumis Inc(ALMS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.81 | Insider Own | 28.54% | Shs Outstand | 124.5M | Perf Week | 4.7% |
| Market Cap | 0.95B | Forward P/E | - | EPS next Y | 13.66% | Insider Trans | 2.34% | Shs Float | 95.4M | Perf Month | -2.19% |
| Enterprise Value | 0.49B | PEG | - | EPS next Q | -0.75 | Inst Own | 67.14% | Short Float | 11.62% | Perf Quarter | -75.37% |
| Income | -0.44B | P/S | 128.62 | EPS this Y | -14.16% | Inst Trans | 3.04% | Short Ratio | 4.31 | Perf Half Y | -68.85% |
| Sales | 0.01B | P/B | 2.03 | EPS next 5Y | 10.01% | ROA | -74.94% | Short Interest | 11.08M | Perf YTD | -26.95% |
| Book/sh | 3.52 | P/C | 1.89 | EPS past 3/5Y | -9.85% - | ROE | -93.65% | 52W High | -77.26% ($31.35) | Perf Year | 48.23% |
| Cash/sh | 3.76 | P/FCF | - | Sales past 3/5Y | - | ROIC | -90.74% | 52W Low | 62.6% ($4.39) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 15.36% | Gross Margin | 52.31% | Volatility(W/M) | 6.41% 6.12% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 65.67 | Sales Y/Y TTM | -63.11% | Oper. Margin | -5479.55% | ATR (14) | 0.53 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.74 | EPS Q/Q | -243.88% | Profit Margin | -5933.45% | RSI (14) | 41.18 | Recom | 1.3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.74 | Sales Q/Q | -37.66% | SMA20 | 5.97% ($6.73) | Beta | -0.35 | Target Price | $31.12 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/8/13 | SMA50 | -32.25% ($10.52) | Rel Volume | 0.95 | Prev Close | $6.64 |
| Employees | 224 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | -44.85% -54.49% | SMA200 | -66.97% ($21.59) | Avg Volume(3M) | 2.57M | Price | $7.13 |
| IPO | 2024/6/28 | Option/Short | Yes/Yes | Trades | 11496 | Volume | 2,431,759 | Change | 7.38% |
🧬 This is a US biopharmaceutical company developing next-generation oral targeted therapies for autoimmune diseases. It focuses on oral inhibitors that precisely modulate immune signaling pathways, targeting immune-mediated diseases such as psoriasis, lupus, and neuroinflammation. The company is pursuing entry into the autoimmune market with a late-stage clinical lead candidate and a pipeline expanded through acquisitions.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
ALMS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -14.2% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $12,862. Peers typically go for $1,237.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 67.1%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #162 of 594 in the industry
Based on market cap of $952M.
FAQ
What kind of company is ALMS?
ALMS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALMS?
The market cap of ALMS is approximately $952M, ranking 2,625 within its sector.
What is the 52-week high and low for ALMS?
ALMS has recorded a 52-week high of $31.35 and a low of $4.39.
